ArticleRheumatology international2025
Low influenza, pneumococcal and herpes zoster vaccination coverage in Australian patients commencing a biologic or targeted synthetic disease modifying anti-rheumatic drug for inflammatory arthritis: a nationwide cross-sectional data linkage study.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cost-effectiveness of herpes zoster vaccination in patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2026Article
- Recombinant zoster vaccine immunization rate in patients on Janus kinase inhibitors for rheumatologic and dermatologic conditions.Rheumatology advances in practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Vaccine-preventable infections, such as herpes zoster (HZ), influenza, and pneumococcal disease are major contributors to morbidity and mortality in patients with inflammatory arthritis. To determine national vaccination coverage against influenza, S. pneumoniae and herpes zoster (HZ) in Australian patients dispensed the first script of a b/tsDMARD for inflammatory arthritis (IA). National data was used to determine the number of patients who received vaccination against S. pneumoniae and HZ within 6 months of commencement of the first Pharmaceutical Benefits Scheme (PBS)-subsidised b/tsDMARD for treatment of IA between 1 Feb 2019 and 31 Dec 2021. As the influenza vaccine is funded annually under the National Immunisation Programme, influenza vaccination within 12 months of the first PBS-subsidised b/tsDMARD was determined. Overall, 72.6% (n = 11,225/15,460) of patients underwent influenza vaccination within 12 months of b/tsDMARD initiation. An adjuvanted or high-dose influenza vaccine preparation was used in 27.9% of 60-69 yo, 82.5% of 70-79 yo and 80.3% of ≥ 80 yo. Only 9.7% (n = 1500/15,460) received a pneumococcal vaccine and 2.4% (n = 367/15,460) received HZ vaccination (Zostavax or Shingrix) within 6 months of b/tsDMARD commencement. There was only a small difference in HZ vaccination coverage in those commencing a Janus Kinase inhibitor compared to a bDMARD (3.3% versus 2.1%, respectively, p < 0.001). Vaccination rates in patients initiating a b/tsDMARD for the treatment of inflammatory arthritis in Australia should be improved. This may also apply to patients with IA in other countries.
Indexed as
Identifiers
41231258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.